Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________ TO___________ Commission file number 1-16671 AMERISOURCEBERGEN CORPORATION (Exact name of registrant as specified in its charter) Delawa ...

| --- | --- | --- | --- | --- | --- | |----------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | J.P. Morgan | | | | | | | Healthcare | | | | | | | Conference JANUARY 2022 | | | | | | | Steve Collis Chairman, President & CEO | | | | | | Cautionary Note Regarding Forward-Looking Statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securitie ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________ TO___________ | --- | --- | --- | --- | |---------------------------------------------------|--------------------------------------|-------------- ...

| --- | --- | --- | |-----------------------------|-------|-------| | | | | | | | | | Q4 FY2021 Financial Results | | | | November 4, 2021 | | | Cautionary note regarding forward-looking statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the "Securities Exchange Act"). Words such as "expect," "likely," "outlook," "forecast," "would," "could ...

Financial Data and Key Metrics Changes - Adjusted diluted EPS for Q4 was $2.39, an increase of 26.5% driven by strong performance in the Pharmaceutical Distribution Services segment and a full quarter contribution from Alliance Healthcare [23][24] - Consolidated revenue for Q4 was $58.9 billion, up approximately 20%, reflecting growth in pharmaceutical distribution and other segments [23][24] - Consolidated gross profit was $2 billion, up 51%, with a gross profit margin of 3.4%, which is 71 basis points higher than the prior year [24][25] - Consolidated operating income was $694 million, up 31%, with an operating income margin of 1.18%, an increase of 10 basis points [25][26] Business Line Data and Key Metrics Changes - Pharmaceutical Distribution Services segment revenue was $51.2 billion, up 8%, driven by increased sales of specialty products and positive prescription utilization trends [26][27] - Operating income for the Pharmaceutical Distribution Services segment increased by 11% to $472 million, with an operating income margin of 0.92% [27] - Other revenue, which includes Alliance Healthcare, was $7.7 billion, up from $2 billion in the prior year, driven by the full quarter's contribution from Alliance Healthcare [27][28] Market Data and Key Metrics Changes - The company distributed over 75 million COVID-19 vaccines to patients in over 30 countries, leveraging its global footprint [8][11] - The animal health business experienced increased demand due to growth in pet ownership, supporting veterinary practices [9][30] Company Strategy and Development Direction - The company aims to capitalize on its strategic priorities and continue executing and innovating in fiscal 2022 [5][21] - Focus on expanding leadership in specialty distribution and enhancing relationships with upstream and downstream customers [10][19] - The company is committed to maintaining strong investment-grade credit ratings and strategic capital deployment [12][42] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate the evolving healthcare landscape and emphasized the importance of innovation and operational excellence [18][21] - The company anticipates continued strong performance across its businesses, despite potential headwinds from COVID-19 therapy sales [49][72] Other Important Information - The company completed the acquisition of Alliance Healthcare and extended its contract with Walgreens through 2029 [22][36] - A significant technology investment was made to improve efficiency and support continuity in operations [12][43] Q&A Session Summary Question: Insights on U.S. drug distribution and COVID-19 therapies - Management does not expect to repeat the benefits from COVID therapies seen in fiscal 2021, with a projected $0.03 benefit in Q1 of fiscal 2022 [48][49] Question: Guidance on international healthcare segment and Profarma Specialty sale - The sale of Profarma Specialty is expected to create a 2% headwind for the International Healthcare Solutions segment's operating income [54][55] Question: Impact of freight costs on business - Higher expenses related to picking, packing, and shipping are fully reflected in the fiscal year 2022 guidance [57][58] Question: Growth expectations for MWI Animal Health and consulting businesses - MWI Animal Health is expected to grow at a higher rate than the overall segment, benefiting from increased pet ownership [60][61] Question: Implications of Medicare negotiating drug prices - Management is not significantly concerned about the impacts of Medicare negotiations on specialty products, emphasizing the importance of preserving innovation [64] Question: Capital deployment expectations - The majority of free cash flow will be directed towards paying down debt from the Alliance Healthcare acquisition [66][67]

| --- | --- | |-----------|-------| | | | | Q3 FY2021 | | Cautionary note regarding forward-looking statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"). Words such as "expect," "likely," "outlook," "forecast," "would," "could," "should," "can," "project," "intend," "plan," "continue," " ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | |-------------------------------------------------------|----------------------------------------|------------------|---------------------------------------- ...

AmerisourceBergen Corporation (ABC) Q2 2021 Earnings Conference Call May 5, 2021 8:30 AM ET Company Participants Bennett Murphy - SVP of IR Steve Collis - Chairman, President & CEO Jim Cleary - Executive VP & CFO Conference Call Participants Glen Santangelo - Guggenheim Eric Coldwell - Baird Lisa Gill - JPMorgan Robert Jones - Goldman Sachs Ricky Goldwasser - Morgan Stanley Eric Percher - Nephron Research Charles Rhyee - Cowen Steven Valiquette - Barclays Kevin Caliendo - UBS George Hill - Deutsche Bank Ope ...

AmerisourceBergen Q2 FY2021 Financial Results May 5, 2021 Cautionary note regarding forward-looking statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Securities Exchange Act"). Words such as "expect," "likely," "outlook," "forecast," "would," "could," "should," "can," "project," "intend," "plan," "continue," " ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM ___________ TO___________ Commission file number 1-16671 AMERISOURCEBERGEN CORPORATION (Exact name of registrant as specified in its charter) Delaware ...